SSY Group (HKSE:02005) Tax Provision : HK$-254 Mil (TTM As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is SSY Group Tax Provision?

SSY Group's tax provision for the six months ended in Dec. 2023 was HK$-133 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-254 Mil.

SSY Group Tax Provision Historical Data

The historical data trend for SSY Group's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SSY Group Tax Provision Chart

SSY Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

-223.84

-114.40

-160.10

-209.60

-254.28

SSY Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Tax Provision	Get a 7-Day Free Trial															-99.16	-137.74	-71.86	-121.19	-133.09

SSY Group Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-254 Mil.

SSY Group (HKSE:02005) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SSY Group Ltd (HKSE:02005) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

N/A

Address

Central Plaza, 18 Harbour Road, Rooms 4902-03, 49th Floor, Wanchai, Hong Kong, HKG

Website

http://www.ssygroup.com.hk

SSY Group Ltd is engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, which includes finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The company has two reportable segments including intravenous infusion solution and others and medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials.

SSY Group (HKSE:02005) Headlines

No Headlines